Background: Magnesium sulfate is an accepted intervention for fetal neuroprotection. There are some perceived differences in the international recommendations on the use magnesium sulfate for fetal neuroprotection in preterm labor. Content: This systematic review analyses the available clinical guidelines for the use of magnesium sulfate for fetal neuroprotection and compares the recommendations, and assesses the quality of guidelines. This provides the consensus, differences and explores the areas for future collaborative research. We searched databases of PUBMED, EMBASE, COCHRANE, Web of Science, LILACS; and included the national and the international clinical practice guidelines. We included seven guidelines out of 227 search results. We evaluated the methodological quality of guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE II) tool and systematically extracted guideline characters, recommendation and supporting evidence base. Summary: Five guidelines were of high quality and two were of moderate quality. One guideline achieved more than an 80% score in all the domains of AGREE II tool. All guidelines recommend use of magnesium sulfate for fetal neuroprotection. However, there are differences in other recommendations such as upper gestational age,
Introduction
Preterm birth, spontaneous and iatrogenic, is associated with a significant risk of neonatal morbidity and mortality [1] . Although survival rates for preterm infants have increased, there is a substantial risk of medical complications and neurodevelopmental impairment [2] . The earlier the gestational age at birth, the higher is the risk. Intrauterine insults such as infection, inflammation, hypoxic ischemic encephalopathy and low birth weight are other risk factors associated with neurodevelopmental impairment [3] [4] [5] . The most frequently associated neurological outcomes are cerebral palsy and cognitive impairments [3] . The risk of cerebral palsy is increased by 30-80-fold in infants born before 30 weeks compared to term infants [4, 6, 7] . Other neurological morbidities include blindness, deafness, gross motor dysfunction, learning difficulties and developmental delay [6, 8, 9] .
Several clinical studies and systematic reviews have evaluated the benefits and harm of antenatal administration of magnesium sulfate for fetal neuroprotection [5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, there are still some controversies regarding the benefits, maternal and fetal side effects, appropriate dose and timing of administration, and the appropriate gestational age at which the intervention is beneficial [21, 22] .
Guidelines are systematically developed statements based on the best available evidence [23] . Evidence based guidelines have been developed to assist healthcare providers achieve the best outcomes for their patients [24] . The development of effective guidelines requires the authors to follow standardized development methods and robust methodological quality [25] . The purpose of this systematic review is to critically appraise and systematically review the available national and international clinical practice guidelines for the antenatal use of magnesium sulfate therapy for fetal neuroprotection and compare the recommendations, evidence base, and assess the quality of guidelines. This in turn would allow identification of international consensus, differences and areas for future collaborative research.
Methods

Sources
A protocol with defined objectives, criteria for guideline selection and approaches to assessing outcomes was developed and registered with the PROSPERO (International Prospective Register of Systematic reviews) (Centre for Reviews and Dissemination; CRD42017071491, University of York, UK). This review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [26, 27] .
The initial literature search was performed by a clinical librarian (KN), and then independently by the first and second authors (PJ and MM) to compare the accuracy of search. Electronic databases of PUBMED, EMBASE, COCHRANE database, LILACS and Web of Science were searched for relevant guidelines using keywords of "preterm", "magnesium sulfate" "fetal neuroprotection" and "guidelines". In addition, guidelines websites such as the National Guideline Clearing House, the National Institute for Health and Clinical Excellence (NICE), the Scottish Intercollegiate Guidelines Network, and obstetrics and gynecology associations or relevant professional societies such as the American College of Obstetrics and Gynecology, the Royal College of Obstetricians and Gynaecologists, the Society of Obstetricians and Gynaecologists of Canada, the American Academy of Family Physicians (AAFP), the Belgian Healthcare Knowledge Centre and the World Health Organization, were searched for additional guidelines.
Guideline selection
All titles and abstracts were screened by two authors (PJ and MM) independently to select the relevant guidelines as per the defined selection criteria and a group consensus was achieved by the two primary authors (PJ and MM) for the included guidelines. The two primary reviewers then independently screened the full contents of all selected guidelines and rigorously assessed the eligibility based on the inclusion and exclusion criteria provided below. Any discrepancies between the reviewers were resolved by discussion.
Multidisciplinary clinical guidelines on the use of magnesium sulfate for the purpose of fetal neuroprotection were included with the following inclusion and exclusion criteria. 
Inclusion criteria
Recommendations for clinical practice and supporting research evidence
Two independent reviewers (PJ and MM) extracted and mapped the pre-specified domains based on the descriptive analysis.
Descriptive analysis was undertaken to describe the general characteristics and recommendations in each guideline. Selected guidelines were reviewed for general descriptions such as year of publication, updates if they were part of preterm guidelines or separate guidelines, number of recommendations, level of evidence for recommendations and grading of recommendations [28] .
The following pre-specified recommendation domains included: use of magnesium sulfate for fetal neuroprotection recommended, an upper gestational age for the use of magnesium sulfate, recommended dose and duration, use of magnesium sulfate irrespective of cause of preterm labor and plurality, repeat dose recommended if the patient had not given birth in 24 h, recommended to discontinue other tocolytics with magnesium sulfate and recommended to monitor adverse effects. A recently published systematic review of guidelines on preterm birth includes international, national and regional guidelines and reviews all general aspects of preterm birth [29] . With regards to use of magnesium sulfate, this previously published review addresses only one question: "if magnesium sulfate is recommended or not in preterm labor for fetal neuroprotection". This current systematic review is focused on in depth assessment of national and international guidelines with specific focus on use of magnesium sulfate for fetal neuroprotection, which is a significant and topical issue. We have reviewed nine recommendations in each included guidelines.
Quality assessment
The Appraisal of Guidelines Research and Evaluation (AGREE II) tool was used for assessing the methodological quality of each guideline [30, 31] . The appraisal was performed on the online AGREE II guideline appraisal tool (http://www.agreetrust.org/appraisal). Each of the 23 items in the six domains of the AGREE II tool is assessed on a seven-point scale response based on key methodological principles. A score of 1 indicates an absence of information or that the concept is very poorly reported. A score of 7 means that the quality of reporting is exceptional, and all of the criteria and considerations articulated in the user's manual were met. A score between 2 and 6 indicates that the reporting of the AGREE II item does not fully comply with criteria or considerations. The percentage of maximum score in each domain was calculated. The guidelines were assessed and scored by two authors (PJ and MM), and any discrepancies resolved by consensus and discussion with the senior author (SL).
Analysis
A guideline score was calculated by the summation of the pre-specified domains and standardized using a prescribed equation [30] . Guidelines were categorized into low quality (0-33%), moderate quality (34-66%) and high quality (67-100%).
Results
Literature search and guidelines selection
The literature search in electronic databases and websites of relevant professional bodies yielded 227 results. After screening, titles and abstracts against inclusion and exclusion criteria and removal of duplicates nine full papers were reviewed. Two were excluded as they were a committee opinion or did not include recommendations for magnesium sulfate for fetal neuroprotection [32, 33] . Seven guidelines were incorporated for systematic review. Figure 1 shows the PRISMA flow diagram of the literature search.
General characteristics of guidelines
Three (ANZ, SOGC, RCPI) of the seven guidelines were separate guidelines specifically addressing the topic of magnesium sulfate use for fetal neuroprotection. In the remaining four guidelines, the topic of magnesium sulfate for fetal neuroprotection was included in the general guidelines of prevention and management of preterm labor. Year of publication ranged from 2010 to 2017. The RCPI guidelines were the only ones that were updated (2013). All the included guidelines were from the professional bodies. Details of guidelines characteristics are presented in Table 1 .
Recommendations for clinical use
All of the seven reviewed guidelines recommend the use of the magnesium sulfate for fetal neuroprotection in premature labor. The recommendation to use magnesium sulfate was the first recommendation in all the guidelines. The evidence level was 1 and recommendation GRADE was level A, in three guidelines (SOGC, ANC, CNGOF), moderate evidence level and a strong recommendation was reported by the WHO and high level of evidence and strong recommendation was given by the KCE. Other guidelines did not report the evidence level and GRADE for recommendations. The number of recommendation statements varied from 1 to 11. Two guidelines with one recommendation statement did include the recommendation for using magnesium sulfate, upper gestational age and duration of use. In six guidelines the upper gestational age for the use of magnesium sulfate was 32 weeks, whereas the NICE guidelines recommends to offer up to 29 weeks + 6 days and to consider using up to 33 weeks + 6 days. Four guidelines (SOGC, ANZ, RCPI, NICE) recommend a dosage of 4 g loading dose followed by 1 g/h maintenance dose for 24 h or until birth. The Belgian guidelines recommend use for not more than 24 h but do not recommend a dose. The French guidelines recommend using for 12 h or until birth, while the WHO guidelines do not suggest the dose and timing. Three guidelines (SOGC, ANZ, CNGOF) recommend using irrespective of the cause of preterm labor and another three do not make any recommendation regarding the cause of preterm labor. Three guidelines recommended use of magnesium sulfate irrespective of plurality (ANZ, WHO, CNGOF) and the remaining three did not have any recommendation. Repeating the dose in 24 h was recommended in two guidelines (ANZ and RCPI), while the SOGC suggested there was insufficient evidence to make recommendations and it was not stated in the remaining four guidelines. A recommendation to discontinue other tocolytics with magnesium sulfate was given in the SOGC guidelines and the ANZ guidelines recommends only stopping if there was hypotension, others did not make any recommendations. Four guidelines recommended to monitor adverse effects (ANZ, SOGC, RCPI, NICE) and another two (WHO KCE, and CNGOF) did not make any recommendation (see Table 2 ).
AGREE II scoring
The AGREE II scoring for each guideline is presented in Table 3 . Five guidelines were of overall high quality and two were of moderate quality as per AGREE II collaboration. The scores for each domain varied between the guidelines. The scores in different domains varied from 80% to 98% in ANZ guidelines; from 64% to 92% in SOGC; from 21% to 93% in RCPI; from 86% to 100% in KCE; from 74% to 90% in WHO; from 64% to 100% for NICE; from 29% to 80% in CNGOF. The Belgian KCE achieved more than 80% of maximum score in all the domains, and ANZ, NICE and WHO guidelines did so in five of six domains. Highest scores were achieved in the domain of "scope and purpose" where lowest scores were achieved in the domain of "editorial independence". Editorial independence addresses if the views of the funding body or the competing interests of the members of the committee has any effect on the publication. Low scores mean that they were not recorded, and therefore difficult to ascertain if there was any influence. 
Discussion
All the seven guidelines strongly recommend the use of magnesium sulfate for fetal neuroprotection for preterm fetus, with a high level of the evidence base. Most recommend using up to 32 weeks at a dose of 4 g loading doses and 1 g/h of maintenance, similar to management of severe pre-eclampsia. This is not surprising as the scientific evidence used for making these recommendations is all based on the same available research evidence. This type of international consensus is particularly beneficial when practitioners or patients are moving from country to country, which is not uncommon. Three of the seven were separate guidelines on the use of magnesium sulfate for fetal neuroprotection and in the remaining four the topic was included in the general guidelines on preterm birth. More substantial guidelines, for example, the NICE guidelines which has 247 pages, can sometimes make it difficult to find the required recommendations for busy clinicians. The rigor of development and clarity of presentation was proper in all the guidelines, but the applicability did not score well.
Although there is good evidence of the benefits and the use of magnesium sulfate is recommended in many international guidelines, there are many units which have yet to implement these recommendations [41, 42] . The challenges for implementation may be multifactorial, including the availability of resources [43] . There is also a lack of consensus on repeating dosage, use in multiple pregnancies and concomitant use with other tocolytics, which in turn reflects a lack of adequate evidence base. A recent meta-analysis of individual patient data showed that there was no significant difference in the treatment effect of antenatal magnesium sulfate based on gestational age, cause of preterm birth, the total dose given and whether a maintenance dose was used. Benefits were noted regardless of these variations [44] . However, individual organization level guidelines and protocols should include these recommendations to assist clinicians based on the best available evidence, as applicable locally [45] .
Recommendations from guidelines reflect available evidence and therefore are likely to be similar when that evidence is available to all. There may not be a valid recommendation that can be made, or the recommendations may vary based on opinions if there is no substantial or agreed evidence base. These areas, where clinically important, should become the focus of future research and international collaboration. Given the importance that effective neuroprotection can offer to the preterm fetus with long term minimization of disability the areas of uncertainty outlined above should be addressed without delay.
Conclusion
All the reviewed international guidelines uniformly recommend the use of magnesium sulfate for fetal neuroprotection in preterm birth. There are some differences in recommendations on an upper limit of gestational age to use, repeating dosage if delivery does not occur, and concomitant use of tocolytics and duration of use.
Future research and international collaboration should focus on areas where there is not sufficient evidence to make international consensual recommendations. Future guidelines should include recommendations on all aspects of magnesium sulfate therapy for fetal neuroprotection and individual organizations should develop their guidelines incorporating local applicability and continue to audit the outcomes. The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
